Session Type: 1,5-hour Oral Session
Session Title: 1,5-hour Oral Session
Authors(s): P.M. Juiz (1), S. Méndez (1), I. Losada (2), N. Somaza (1), M. Rodríguez (3), G. Barbeito (4), F.J. Vasallo (5), M.I. Paz (6), F. García (7), M.V. Pulián (8), M. Serrano (9), J. Alba (10), P. Alonso (11), A. Agulla (1)
Authors Affiliations(s): (1) CHUF, Spain, (2) Servizo de Epidemioloxía, Spain, (3) CHUAC, Spain, (4) CHUS, Spain, (5) CHUVI, Spain, (6) CHUO, Spain, (7) HULA, Spain, (8) CHOP, Spain, (9) Hospital da Costa, Spain, (10) Hospital Comarcal do Barco de Valdeorras, Spain, (11) Hospital Comarcal de Monforte de Lemos, Spain
Background:
Vaccination against Streptococcus pneumoniae with polysaccharidic 23-valent antipneumococcal vaccine (PPSV23) was authorized in 2000 in Galicia (Spain) for ≥65 years-old belonging to risk groups. In 2001 vaccination with antipneumococcal 7-valent conjugated vaccine (PCV7) was authorized for children in risk groups. In 2011, systematic vaccination in children with antipneumococcal 13-valent conjugated vaccine (PCV13) was established. The aim of this study is to analyze the behavior of PCV13 and PPSV23 serotypes through the study period.
Methods:Every invasive pneumococcal disease (IPD)-causing isolate in adults was collected from sterile bodily fluids (2088 samples) between 2011 and 2018. Serotyping was performed by latex agglutination and Quellung reaction (Statens Serum Institut latex/antisera, Copenhagen, Denmark). Incidences were described in cases/100,000 inhabitants.
Results:IPD incidence has increased from 10,69 in 2011 to 15,55 in 2018. PCV13 incidence has decreased from 6,70 to 2,72, but non-PCV13/PPSV23 has increased from 1,83 to 8,43.
Regarding to PCV13/non-PCV7, serotype 3 has maintained its incidence, and serotypes 19A and 7F have decreased drastically. 1, 5 and 6A weren’t almost present from the beginning of the study. PCV7 were also less present, except 14 and 4, which decreased.
For PPSV23/non-PCV13, 12F, 9N and 22F have increased, and specially serotype 8, becoming the most prevalent in 2018 (29,72% of all cases). Data are shown in table below.
Conclusions:
After 8 years of systematic children vaccination with PCV13, IPD incidence in adults has increased, but PCV13-related IPD has decreased substantially.
There’s been an increase in the PPSV23 serotypes not included in PCV13, specially serotype 8, the most prevalent in 2018.
Keyword(s): Streptococcus pneumoniae, VaccineSession Type: 1,5-hour Oral Session
Session Title: 1,5-hour Oral Session
Authors(s): P.M. Juiz (1), S. Méndez (1), I. Losada (2), N. Somaza (1), M. Rodríguez (3), G. Barbeito (4), F.J. Vasallo (5), M.I. Paz (6), F. García (7), M.V. Pulián (8), M. Serrano (9), J. Alba (10), P. Alonso (11), A. Agulla (1)
Authors Affiliations(s): (1) CHUF, Spain, (2) Servizo de Epidemioloxía, Spain, (3) CHUAC, Spain, (4) CHUS, Spain, (5) CHUVI, Spain, (6) CHUO, Spain, (7) HULA, Spain, (8) CHOP, Spain, (9) Hospital da Costa, Spain, (10) Hospital Comarcal do Barco de Valdeorras, Spain, (11) Hospital Comarcal de Monforte de Lemos, Spain
Background:
Vaccination against Streptococcus pneumoniae with polysaccharidic 23-valent antipneumococcal vaccine (PPSV23) was authorized in 2000 in Galicia (Spain) for ≥65 years-old belonging to risk groups. In 2001 vaccination with antipneumococcal 7-valent conjugated vaccine (PCV7) was authorized for children in risk groups. In 2011, systematic vaccination in children with antipneumococcal 13-valent conjugated vaccine (PCV13) was established. The aim of this study is to analyze the behavior of PCV13 and PPSV23 serotypes through the study period.
Methods:Every invasive pneumococcal disease (IPD)-causing isolate in adults was collected from sterile bodily fluids (2088 samples) between 2011 and 2018. Serotyping was performed by latex agglutination and Quellung reaction (Statens Serum Institut latex/antisera, Copenhagen, Denmark). Incidences were described in cases/100,000 inhabitants.
Results:IPD incidence has increased from 10,69 in 2011 to 15,55 in 2018. PCV13 incidence has decreased from 6,70 to 2,72, but non-PCV13/PPSV23 has increased from 1,83 to 8,43.
Regarding to PCV13/non-PCV7, serotype 3 has maintained its incidence, and serotypes 19A and 7F have decreased drastically. 1, 5 and 6A weren’t almost present from the beginning of the study. PCV7 were also less present, except 14 and 4, which decreased.
For PPSV23/non-PCV13, 12F, 9N and 22F have increased, and specially serotype 8, becoming the most prevalent in 2018 (29,72% of all cases). Data are shown in table below.
Conclusions:
After 8 years of systematic children vaccination with PCV13, IPD incidence in adults has increased, but PCV13-related IPD has decreased substantially.
There’s been an increase in the PPSV23 serotypes not included in PCV13, specially serotype 8, the most prevalent in 2018.
Keyword(s): Streptococcus pneumoniae, Vaccine